Condition: Pancreatic Cancer Metastatic · Pancreatic Ductal Adenocarcinoma · Pancreatic Cancer Stage IV · Sponsor: Panbela Therapeutics, Inc.
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.
This description comes directly from the study's public registry record.
Rachel Bragg, MPH · 952-479-1196 · rbragg@panbela.com
Tammy Groene · 952-479-1196 · tgroene@panbela.com
Always discuss trial participation with your own doctor first.
| Genesis Cancer and Blood Institute (SCRI) | Hot Springs, Arkansas, United States | Withdrawn |
| Providence Medical Foundation | Fullerton, California, United States | Recruiting |
| Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| MedStar Georgetown University Hospital | Washington D.C., District of Columbia, United States | Active Not Recruiting |
| Henry Ford Health System | Detroit, Michigan, United States | Recruiting |
| CentraCare Health | Saint Cloud, Minnesota, United States | Withdrawn |
| Columbia University Medical Center | New York, New York, United States | Recruiting |
| University of Rochester | Rochester, New York, United States | Recruiting |
| Mark H Zangmeister Center - SCRI - PPDS | Columbus, Ohio, United States | Terminated |
| Tennessee Oncology NASH - SCRI - PPDS | Nashville, Tennessee, United States | Active Not Recruiting |
| HOPE Cancer Center of East Texas | Tyler, Texas, United States | Recruiting |
| Medical Oncology Associates - Spokane | Spokane, Washington, United States | Recruiting |
+ 81 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05254171